CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial

医学 阿糖胞苷 柔红霉素 内科学 髓系白血病 髓性白血病 化疗 化疗方案 肿瘤科 儿科
作者
Jeffrey E. Lancet,Geoffrey L. Uy,Laura F. Newell,Tara L. Lin,Ellen Kelly Ritchie,Robert Kenneth Stuart,Stephen Anthony Strickland,Donna E. Hogge,Scott R. Solomon,Dale Lee Bixby,Jonathan E. Kolitz,Gary John Schiller,Matthew Joseph Wieduwilt,Daniel H. Ryan,Stefan Faderl,Jörge E. Cortes
出处
期刊:The Lancet Haematology [Elsevier BV]
卷期号:8 (7): e481-e491 被引量:230
标识
DOI:10.1016/s2352-3026(21)00134-4
摘要

Summary

Background

Daunorubicin and cytarabine are used as standard induction chemotherapy for patients with acute myeloid leukaemia. CPX-351 is a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio. Primary analysis of the phase 3 trial in adults aged 60–75 years with newly diagnosed high-risk or secondary acute myeloid leukaemia provided support for approval of CPX-351 by the US Food and Drug Administration and European Medicines Agency. We describe the prospectively planned final 5-year follow-up results.

Methods

This randomised, open-label, multicentre, phase 3 trial was done across 39 academic and regional cancer centres in the USA and Canada. Eligible patients were aged 60–75 years and had a pathological diagnosis of acute myeloid leukaemia according to WHO 2008 criteria, no previous induction therapy for acute myeloid leukaemia, and an Eastern Cooperative Oncology Group performance status of 0–2. Patients were randomly assigned 1:1 (stratified by age and acute myeloid leukaemia subtype) to receive up to two induction cycles of CPX-351 (100 units/m2 administered as a 90-min intravenous infusion on days 1, 3, and 5; on days 1 and 3 for the second induction) or standard chemotherapy (cytarabine 100 mg/m2 per day continuous intravenous infusion for 7 days plus intravenous daunorubicin 60 mg/m2 on days 1, 2, and 3 [7+3]; cytarabine for 5 days and daunorubicin on days 1 and 2 for the second induction [5+2]). Patients with complete remission or complete remission with incomplete neutrophil or platelet recovery could receive up to tw cycles of consolidation therapy with CPX-351 (65 units/m2 90-min infusion on days 1 and 3) or chemotherapy (5+2, same dosage as in the second induction cycle). The primary outcome was overall survival analysed in all randomly assigned patients. No additional adverse events were collected with long-term follow-up, except data for deaths. This trial is registered with ClinicalTrials.gov, NCT01696084, and is complete.

Findings

Between Dec 20, 2012, and Nov 11, 2014, 309 patients with newly diagnosed high-risk or secondary acute myeloid leukaemia were enrolled and randomly assigned to receive CPX-351 (153 patients) or 7+3 (156 patients). At a median follow-up of 60·91 months (IQR 60·06–62·98) in the CPX-351 group and 59·93 months (59·73–60·50) in the 7+3 group, median overall survival was 9·33 months (95% CI 6·37–11·86) with CPX-351 and 5·95 months (4·99–7·75) with 7+3 (HR 0·70, 95% CI 0·55–0·91). 5-year overall survival was 18% (95% CI 12–25%) in the CPX-351 group and 8% (4–13%) in the 7+3 group. The most common cause of death in both groups was progressive leukaemia (70 [56%] of 124 deaths in the CPX-351 group and 74 [53%] of 140 deaths in the 7+3 group). Six (5%) of 124 deaths in the CPX-351 group and seven (5%) of 140 deaths in the 7+3 group were considered related to study treatment.

Interpretation

After 5 years of follow-up, the improved overall survival with CPX-351 versus 7+3 was maintained, which supports the previous evidence that CPX-351 can contribute to long-term remission and improved overall survival in patients aged 60–75 years with newly diagnosed high-risk or secondary acute myeloid leukaemia.

Funding

Jazz Pharmaceuticals.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
兴奋石头发布了新的文献求助10
1秒前
bingrui完成签到,获得积分10
1秒前
1秒前
dean发布了新的文献求助10
2秒前
烟花的应助被大宝宝采纳,获得10
2秒前
香蕉觅云的应助被蛋堡采纳,获得10
4秒前
充电宝的应助被ke采纳,获得10
4秒前
CSY完成签到 ,获得积分10
4秒前
fzw完成签到 ,获得积分10
4秒前
独特背包完成签到,获得积分10
5秒前
跳跃的雯发布了新的文献求助10
5秒前
5秒前
kxmmmy完成签到,获得积分10
6秒前
打打的应助被jiao采纳,获得10
6秒前
6秒前
丘比特的应助被香香香采纳,获得10
7秒前
余香的应助被cc采纳,获得10
7秒前
顾北发布了新的文献求助10
7秒前
8秒前
上官若男的应助被普鲁卡因采纳,获得10
9秒前
summer完成签到,获得积分10
9秒前
傢誠完成签到,获得积分10
9秒前
热诚完成签到 ,获得积分10
9秒前
CSY关注了科研通微信公众号
9秒前
10秒前
Maestro_S的应助被这次会赢吗采纳,获得10
10秒前
内向的果汁完成签到,获得积分10
11秒前
Heimdall完成签到,获得积分10
11秒前
慕青的应助被kinsley采纳,获得10
11秒前
DuMilk完成签到,获得积分10
11秒前
123发布了新的文献求助10
12秒前
12秒前
yuxaomam完成签到,获得积分10
13秒前
CodeCraft的应助被苹果黄豆采纳,获得10
13秒前
共享精神的应助被cc采纳,获得10
13秒前
刀河王发布了新的文献求助10
14秒前
14秒前
14秒前
cdercder的应助被jun采纳,获得10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187592
求助须知:如何正确求助?哪些是违规求助? 9575705
关于积分的说明 21842471
捐赠科研通 7785407
什么是DOI,文献DOI怎么找? 3435057
关于科研通互助平台的介绍 2559461
邀请新用户注册赠送积分活动 2481952